Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 9, 2015
Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna AssayAleix Prat, Patricia Galván, Begoña Jimenez, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 22, 2010
Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptorMaurizio Scaltriti, Sarat Chandarlapaty, Ludmila Prudkin, et al.Journal for Immunotherapy of Cancer|August 11, 2025
First-in-human phase 1 study of the ICOS agonist feladilimab on patients with advanced solid tumorsMichele Maio, Victor Moreno, Juan Martin-Liberal, et al.Leukemia & Lymphoma|March 19, 2024
Momelotinib vs. ruxolitinib in myelofibrosis patient subgroups by baseline hemoglobin levels in the SIMPLIFY-1 trialVikas Gupta, Stephen Oh, Timothy Devos, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 5, 2014
Double-blind, placebo-controlled, multicenter, randomized, phase IIb neoadjuvant study of letrozole-lapatinib in postmenopausal hormone receptor-positive, human epidermal growth factor receptor 2-negative, operable breast cancerValentina Guarneri, Daniele Giulio Generali, Antonio Frassoldati, et al.The Oncologist|June 16, 2021
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid TumorsHui K Gan, Michael Millward, Mathilde Jalving, et al.Cancer Chemotherapy and Pharmacology|February 17, 2020
Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumorsAnthony W Tolcher, Razelle Kurzrock, Vincente Valero, et al.BJC Reports|February 27, 2025
CITRINO: phase 1 dose escalation study of anti-LAG-3 antibody encelimab alone or in combination with anti-PD-1 dostarlimab in patients with advanced/metastatic solid tumoursJ Randolph Hecht, Jean-Marie Michot, David Bajor, et al.Clinical Lymphoma, Myeloma & Leukemia|November 8, 2024
Longitudinal Assessment of Transfusion Intensity in Patients With JAK Inhibitor-Naive or -Experienced Myelofibrosis Treated With MomelotinibClaire N Harrison, Ruben Mesa, Moshe Talpaz, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2014
High HER2 expression correlates with response to the combination of lapatinib and trastuzumabMaurizio Scaltriti, Paolo Nuciforo, Ian Bradbury, et al.Pageof 5